Business context and reporting period
The supplied filing is Diffusion Pharmaceuticals Inc.’s Form 10-K for the fiscal year ended December 31, 2016, not a filing under the name Cervomed Inc. Diffusion is a clinical-stage biotechnology company with no approved products or product-sales revenue. Its lead candidate, trans sodium crocetinate (TSC), is being developed to re-oxygenate hypoxic tumors and potentially improve the effects of radiation and chemotherapy.
The January 2016 merger with Diffusion Pharmaceuticals LLC was accounted for as a reverse acquisition, with Diffusion LLC as the accounting acquirer. Accordingly, historical comparisons are primarily against Diffusion LLC’s stand-alone 2015 results and are not fully comparable to the post-merger company.
Financial performance and liquidity
| Metric | 2016 | 2015 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $7.25 million | $3.88 million |
| General and administrative expense | $11.09 million | $2.52 million |
| Operating loss | $18.37 million | $6.41 million |
| Net loss | $18.04 million | $6.72 million |
| Net loss per share, basic and diluted | $1.76 | $2.56 |
| Cash used in operating activities | $10.77 million | $5.19 million |
- Cash and cash equivalents were $1.55 million at year-end, down from $2.00 million. Working capital was a deficit of $2.83 million; current liabilities were $4.44 million.
- Year-end convertible-note principal totaled $2.43 million: $1.88 million due September 2017 at 6% interest and $550,000 due June 2018 at 1%. Contractual principal and interest payments totaled approximately $2.58 million.
- 2016 investing cash inflow of $8.50 million primarily reflected cash acquired in the merger; financing inflow of $1.83 million primarily reflected convertible-note proceeds.
- Margins are not meaningful because the company had no product revenue. The filing reports continuing operating losses and negative operating cash flow.
Material changes and unusual items
- R&D expense increased by $3.38 million, mainly due to animal toxicology, active pharmaceutical ingredient manufacturing and pancreatic-cancer work; the increase was partly offset by lower GBM-trial spending. The filing also recorded a $1.0 million impairment when RES-440 development was abandoned.
- G&A expense increased by $8.57 million, including higher public-company, merger and advisory costs, increased insurance and a $2.5 million noncash litigation-settlement charge.
- The company recorded a $364,796 income-tax benefit related to the RES-440 impairment. It reported an accumulated deficit of $60.19 million at year-end.
- The 2016 loss per share was lower than 2015 despite the higher net loss; weighted-average shares rose from 2.62 million to 10.23 million, in part reflecting the merger and share issuances. The company also effected a 1-for-10 reverse stock split in August 2016.
Outlook, risks and contingencies
- Management expected year-end 2016 cash plus the March 2017 private-placement proceeds to fund operations into December 2017. The auditor highlighted substantial doubt about the company’s ability to continue as a going concern; additional financing is needed and is not assured.
- In March 2017, after the reporting period, the company received approximately $14.1 million net from an initial private-placement closing: 7,837,023 convertible preferred shares at $2.02 each, with a five-year warrant for one common share per preferred share. Further closings could bring aggregate gross proceeds to $25 million. The preferred stock carries an 8% cumulative dividend payable in common shares. These securities may materially dilute existing holders.
- FDA discussions had produced guidance for a planned, randomized, 400-patient Phase 3 GBM trial that could support an approval application if successful. The planned start and timing were conditional on funding and completion of manufacturing and toxicology requirements. A pancreatic-cancer Phase 2 trial was also being planned, subject to funding and FDA discussions. Neither program’s projected timing is assured.
- The company reported promising survival results from a 59-patient Phase 1/2 GBM study, including two-year survival of 36.3% versus 26.5% in a historical control. These were historical comparisons, not results from the planned pivotal randomized trial.
- Key risks include clinical and regulatory failure or delay, financing needs, reliance on third-party manufacturers and CROs, competition, intellectual-property challenges, and potential dilution. The remaining RES-529 intangible asset was carried at $8.64 million and could be substantially impaired if development prospects deteriorate.
- A former CEO’s claim was proceeding in arbitration; the company said the outcome and possible loss could not be estimated and could materially affect its financial position. The separate Schmidt litigation was settled in 2016 through convertible notes, with the $2.5 million settlement charge recorded.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for Diffusion Pharmaceuticals Inc., despite the request metadata naming Cervomed Inc.
- Review the full audited statements and going-concern disclosures, and assess whether subsequent financing and any later funding extended the stated runway.
- Check the terms, conversion and warrant dilution, dividend mechanics, and any additional closings of the March 2017 private placement.
- Verify the status, protocol, funding and regulatory requirements for the planned GBM and pancreatic-cancer trials; assess the evidentiary limits of historical-control GBM results.
- Track convertible-note maturities, the unresolved former-CEO arbitration, and the carrying value and impairment risk of RES-529.